Human peripheral $\gamma\delta$ T cells possess regulatory potential

Anja A. Kühl,^{1,2} Nina N. Pawlowski, 1,3 Katja Grollich, 1,2 Maike Blessenohl,⁴ Jürgen Westermann,⁴ Martin Zeitz,¹ Christoph Loddenkemper^{2,5} and Jörg C. Hoffmann^{1,6}

 1 Medizinische Klinik I, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm, Berlin, ²Research Center ImmunoSciences, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm, Berlin, ³Immatics Biotechnologies, Tübingen, ⁴Institut für Anatomie, Universität Lübeck, Lübeck, ⁵Institut für Pathologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm, Berlin, and ⁶ Medizinische Klinik I, St Marienkrankenhaus, Ludwigshafen, Germany

doi:10.1111/j.1365-2567.2009.03162.x Received 6 April 2009; revised 9 June 2009; accepted 2 July 2009. Correspondence: Dr J. C. Hoffmann, Medizinische Klinik I, St Marienkrankenhaus Ludwigshafen, Salzburger Strasse 15, D-67067 Ludwigshafen, Germany. Email: joerg.hoffmann@ st-marienkrankenhaus.de Senior author: Jörg C. Hoffmann

Summary

Deficiency in $\gamma\delta$ T cells aggravates colitis in animal models suggesting that $\gamma\delta$ T cells have regulatory properties. Therefore, proliferation, suppression and cytokine secretion of human $v\delta$ T cells were determined in vitro. Human peripheral $\gamma\delta$ T cells were isolated from the whole blood of healthy donors by magnetic antibody cell sorting technology. The proliferation after CD3/CD28 stimulation was measured by ${}^{3}[H]$ thymidine incorporation. Interferon- γ (IFN- γ), interleukin-2 (IL-2), transforming growth factor- β (TGF- β) and IL-10 concentrations were measured by enzymelinked immunosorbent assay; TGF- β messenger RNA was also measured by reverse transcription–polymerase chain reaction. The expression of latency associated peptide (LAP), a TGF- β complex component, intracellular cytokine content and T helper cell proliferation were measured by flow cytometry. Human $\gamma\delta$ T cells showed poor proliferation upon CD3/ CD28 stimulation and suppressed T helper cell growth stronger than $CD4^+$ CD25⁺ T cells, although $\gamma\delta$ T cells were FOXP3 negative. They secreted little IL-2 but high concentrations of IFN- γ , IL-10 and TGF- β . When looking at LAP expression the V δ 1 subset was found to be the main TGF- β producer compared to V δ 2 T cells. Taken together, peripheral $\gamma\delta$ T cells have in vitro a more potent regulatory potential than $CD4^+$ $CD25^+$ cells regarding T helper cell suppression. This is most likely the result of strong TGF- β secretion, particularly by the V δ 1 subset.

Keywords: anergy; cytokines; regulatory T cells; suppression; transforming growth factor- β

Introduction

There are two T-cell subsets characterized by their expression of a T-cell receptor (TCR) α chain and a β chain ($\alpha\beta$ T cells) or a γ chain and a δ chain ($\gamma\delta$ T cells). These T-cell subsets do not work in parallel but they act together. For instance, $\gamma \delta$ T cells regulate $\alpha \beta$ T-cell activation via cytokine secretion^{1,2} and assist their local inflammatory function.³ Although $\gamma\delta$ T cells have only a limited repertoire of TCR rearrangements they are capable of responding to various environmental insults, such as exposure to toxin (e.g. ozone), 4 infections, $3,4$ inflammation,⁵⁻¹¹ tumours,^{2,12,13} or epithelial injury.¹⁴⁻¹⁸ Therefore, they have a broad functional armamentarium including secretion of cytokines [e.g. interferon- γ (IFN- γ) or interleukin-10 (IL-10)], cytotoxicity, or secretion of growth factors [keratinocyte growth factor, transforming growth factor- β (TGF- β)] and chemokines. To exert these functions $\gamma \delta$ T cells are mainly situated in the intestinal epithelium, although in humans not quite as frequently as in rodents.

In recent years our understanding of the interaction of $\gamma\delta$ T cells with the epithelium has increased.¹⁸ We now know that $\gamma\delta$ T cells not only support regeneration of epithelium but also attract neutrophils just after tissue injury so as to remove necrotic epithelial cells. In line

Abbreviations: FSC, forward scatter; IBD, inflammatory bowel disease; LAP, latency associated peptide; PBMC, peripheral blood mononuclear cells; SSC, side scatter.

with these findings, depletion of or deficiency in $v\delta$ T cells aggravate inflammation in colitis models that exhibit injury of the epithelial barrier, i.e. 2,4,6-trinitrobenzene sulphonic acid-induced and dextran sulphate sodium-induced colitis.¹⁹ However, depletion of $v\delta$ T cells also increases inflammation in intestinal inflammation in a model without epithelial injury, i.e. $TNF^{AARE} mice.⁷ Similarly, reconstruction of thymectom$ ized non-obese diabetic (NOD) mice with $\gamma \delta$ T cells prevented diabetes in a similar manner to CD4⁺ CD25⁺ regulatory T cells $(Treg).¹¹$ Using oral insulin in euthymic mice require $\gamma \delta$ T cells to induce Treg.¹⁰ Therefore, $\gamma\delta$ T cells seem to interact with $\alpha\beta$ T cells supporting regulatory mechanisms in addition to homeostatic effects on the epithelial barrier.

The following study was conducted to elucidate the properties of peripheral human $\gamma \delta$ T cells in vitro. Therefore, peripheral human $\gamma \delta$ T cells were obtained from healthy donors and examined with respect to their proliferative and suppressive behaviour as well as their cytokine profile. Finally, peripheral $\gamma \delta$ T-cell functions were compared with those of other regulatory T cells (CD4⁺ CD25⁺). In this study, we will show that $\gamma\delta$ T cells have regulatory functions themselves, such as anergy and suppression of T helper cell proliferation. Importantly, $\gamma \delta$ T cells, particularly the V δ 1 subset, were found to be strong TGF- β producers.

Materials and methods

Monoclonal antibodies

The following monoclonal antibodies (mAb) were used in vitro: OKT3 (anti-human CD3; American Type Culture Collection, Manassas, VA); BW828 (anti-human CD28; a gift of Dr Kurrle, Behringwerke AG, Marburg, Germany); B1-phycoerythrin- (PE), fluorescein isothiocyanate- (FITC), biotin-conjugated (anti-human TCR- $\gamma \delta$; BD Biosciences, Heidelberg, Germany); B3.1-PE (anti-human Vy9; BD Biosciences); B6-PE, -FITC (anti-human V δ 2; BD Biosciences); TS-1-FITC (anti-human V δ 1; Endogen, Woburn, MA); 4E3-PE (anti-human CD25-PE; Miltenyi Biotec, Bergisch Gladbach, Germany); RPA-T4-PE, -FITC (anti-human CD4-PE (BD Biosciences); BW135/80-PE (anti-human CD8; Miltenyi Biotec); MQ1-17H12 allophycocyanin (APC; anti-human IL-2; BD Biosciences); MP4-25D2-APC (anti-human IL-4; BD Biosciences); JES3-19F1-APC (anti-human IL-10; BD Biosciences); B27- APC, -FITC (anti-human IFN- γ ; BD Biosciences); 27232-PE [anti-human LAP (TGF- β_1); R&D Systems, Wiesbaden, Germany]; 3G3-APC (anti-human FOXP3; Miltenyi Biotec). OKT3 was purified from supernatants using spinner flasks followed by affinity chromatography employing Protein G–Sepharose (Amersham Biosciences, Freiburg, Germany).

Isolation of peripheral $v\delta$ T cells and subsets

The $v\delta$ T cells were separated from peripheral blood mononuclear cells (PBMC) by magnetic antibody cell sorting (MACS) technology using the TCR- $\gamma \delta^+$ T Cell Isolation kit according to the manufacturer's instruction (Miltenyi Biotec). Mononuclear cells were enriched from 50–100 ml (experiments with $\gamma\delta$ T cells) or 500 ml (experiments with $V\delta1$ and $V\delta2$ T cells) heparinized whole blood from female and male middle-aged healthy donors by Ficoll density centrifugation (Biocoll separating solution; Biochrom AG, Berlin, Germany). Informed consent was obtained from each blood donor. The PBMC were incubated $(15 \text{ min}, 4^{\circ})$ in optimal concentration with PE-labelled anti- $\gamma \delta$ TCR mAb (clone GL3; BD Biosciences). After washing twice with MACS buffer [0-5% bovine serum albumin, 2 mm ethylenediaminetetraacetic acid in phosphate-buffered saline (PBS)] anti-PE MicroBeads (Miltenyi Biotec) were added (1 : 5 dilution) and $\gamma\delta$ T cells were enriched following the manufacturer's instructions. Purity of $\gamma\delta$ T cells was determined by flow cytometry and only cells with > 98% purity were used. Unlabelled $\gamma\delta$ T cells were further separated into V δ 1 and V δ 2 subsets by MACS technology. V δ 2 T cells were labelled with anti-human V δ 2-PE mAb (BD Biosciences) and subsequently with anti-PE beads (Miltenyi Biotec). The V δ 1 and V δ 2 subsets were separated using a mass spectrometry column (Miltenyi Biotec), which is passed by unlabelled V δ 1 T cells while the labelled V δ 2 T cells are retained. $V\delta 2$ T cells were released after removing the column from the magnet.

These $\gamma\delta$ T-cell subsets were stimulated for 3 days in 48well plates with 5 µg/ml concanavalin A (Con A; Sigma, Deisenhofen, Germany). Thereafter, cells were washed three times in PBS, resuspended in RNeasy lysis buffer buffer, shock-frozen in liquid nitrogen, and stored at -80° until quantification of TGF- β messenger RNA (mRNA).

Isolation of human $CD4^+$ $CD25^+$ T cells

To compare regulatory properties of $\gamma \delta$ T cells with those of other human regulatory cells, human CD4⁺ CD25⁺ T cells were isolated from PBMC of whole blood from healthy donors by MACS technology using a CD4⁺ CD25+ Regulatory T Cell Isolation kit (Miltenyi Biotec) following the manufacturer's instructions. Purity of $CD4^+$ $CD25^+$ T cells was determined by flow cytometry and only cells with > 98% purity were used.

Isolation and labelling of human $CD4^+$ T cells

For allogeneic coculture experiments, $CD4⁺$ T cells were isolated from the initial MACS step of the $CD4^+$ $CD25^+$ T-cell isolation, where $CD4^+$ T cells pass the separation column unlabelled. An aliquot was taken and washed, and purity was determined by flow cytometry. Only cells with > 98% purity were used. An aliquot of 10^7 CD4⁺ T cells was resuspended in 1 ml PBS with 1 um carboxyfluorescein succinimidyl ester (CFSE; Fluka, Seelze, Germany). After incubation (10 min, room temperature in the dark), cells were washed twice in complete medium (RPMI-1640 medium containing 10% fetal calf serum, 100 U/ml penicillin/streptomycin, and 3 mm glutamine; PAA, Cölbe, Germany).

For proliferation studies, human $CD4^+$ and $CD8^+$ T cells were isolated from PBMC of healthy donors by MACS technology using CD4 or CD8 beads according to the manufacturer's instructions (Miltenyi Biotec).

Proliferation assay

The proliferation index (stimulated/unstimulated) of CD4⁺, CD8⁺, CD4⁺ CD25⁺ and $\gamma\delta$ T cells was determined via incorporation of [6-³H]thymidine. Cells were incubated in triplicate for 96 hr at 5×10^4 cells/well in 96-well round-bottom plates (NUNC, Wiesbaden, Germany) at 37° in 5% $CO₂$ humidified air. Each well received 0.5 μCi of [6-³H]thymidine (Amersham Pharmacia, Little Chalfont, UK) during the last 18 hr of the 96 hr of culture. Incorporated [6-³H]thymidine was harvested on a glass fibre membrane and detected by liquid scintillation counting (LKB Wallac, Turku, Finland). For standard TCR stimulation, cells were stimulated via plate-bound anti-human CD3 mAb OKT3 $(10 \mu g/ml)$ in the presence of 1 lg/ml soluble anti-human CD28 mAb BW828 with or without 100 U/ml recombinant human IL-2 (Sigma). Additionally, proliferation of CD4⁺, CD8⁺, CD4⁺ CD25⁺ and $\gamma\delta$ T cells was measured after stimulation with 5 μ g/ ml isopentenyl pyrophosphate (Sigma) and 100 U/ml recombinant human (rhu) IL-2.

For determining the suppressive capacity of regulatory T cells, proliferation of CFSE-labelled CD4⁺ T cells was measured in monoculture and coculture with allogeneic $\gamma\delta$ T cells and CD4⁺ CD25⁺ T cells by flow cytometry. Therefore, $CD4^+$ T cells were incubated in triplicates for 6 days at 2×10^5 cells/well in 96-well round-bottom plates (NUNC) coated with anti-CD3 mAb OKT3 (10 µg/ml) in the presence of 1 µg/ml anti-CD28 mAb BW828 with or without 100 U/ml rhuIL-2 (Sigma) at 37° in 5% CO_2 humidified air. In coculture experiments 1×10^5 CD4⁺ T cells/well were incubated under the same conditions as mentioned above with 1×10^5 regulatory T cells/well.

Cytokine assay

CD4⁺, CD4⁺ CD25⁺ and $\gamma\delta$ T cells were incubated at 10⁶ cells/ml in 24-well plates (NUNC) coated with OKT3 (10 μ g/ml) and BW828 (1 μ g/ml) added at 37° in a humidified atmosphere with 5% CO₂. Supernatants were taken after 48 hr and examined for cytokine secretion (IL-2, IL-10, TGF- β and IFN- ν) by sandwich enzymelinked immunsorbent assay using antibodies as well as recombinant protein standards for IL-2, IL-10 and IFN- ν (BD Biosciences), and TGF- β (Promega, Mannheim, Germany) according to the manufacturer's instructions.

Intracellular cytokines of Con A (Sigma) stimulated CD4⁺ CD25⁺ and $\gamma\delta$ T cells were measured by flow cytometry. Therefore, cells were stimulated for 5 days (5 µg/ml Con A) and restimulated with 10 ng/ml phorbol 12-myristate 13-acetate (Sigma) and 1 μ g/ml ionomycin (Calbiochem, Schwalbach, Germany) for 6 hr and 5 µg/ ml brefeldin A (Sigma) for 3 hr. Subsequently, cells were fixed in 2% formalin (Roth, Karlsruhe, Germany) for 20 min at room temperature.

RNA isolation and complementary DNA synthesis

Total RNA was isolated according the manufacturer's protocol (innuPrep RNA minikit; analyticJena, Jena, Germany). To increase the RNA concentration, the final volume of the extracted RNA was reduced (Speed-Vac) and treated with DNase I (Sigma-Aldrich, Munich, Germany). Complementary DNA (cDNA) synthesis was performed with 200 ng of random primer (Promega), 0-1 ^M dithiothreitol $5 \times$ reaction buffer, 0.5 mm dNTP (each obtained from Promega), and 100 U reverse transcriptase Superscript II RNase H (Invitrogen Life Technologies, Karlsruhe, Germany) in a total volume of 20 µl. Samples were incubated at 42° for 50 min.

$TGF-\beta$ mRNA quantification

To analyse the expression of TGF- β genes in human peripheral blood lymphocytes, the RNA was extracted from cells snap frozen in Lysis solution and reverse transcribed as described above. The cDNA was added to the $2 \times$ Taqman-Mastermix (Eurogentec, Köln, Germany) and amplified. For signal detection, the ABI Prism 7000 sequence detector (Applied Biosystems, Darmstadt, Germany) was programmed to an initial step of 6 min at 95° , followed by 50 thermal cycles of 15 seconds at 95° and 1 min at 60° . The following housekeeping gene and TGF- β forward (for) and reverse (rev) primers and probes were designed by using the computer software PRIMER EXPRESS (Primer Express software v2.0; Applied Biosystems): MLN51 for 5'-CTT CAT CTG CGG CGG GTG-3', rev 5'-ACC TTC AAT GCC ATC TTC ACT CT-3' and probe Fam 5'-ACT CCG ACT CCT CAG CAC TCT TGG CG $-3'$ Tamra; TGF- β for $5'$ -TCA GCT CCA CGG AGA AGA ACT-3', TGF- β rev 5'-GTT GGC ATG GTA GCC CCT GG-3' and probe Fam 5'-TCC ACT TCC AGC CGA GGT CCT TGC G-3' Tamra.

The optimal primer concentrations used are 500 nm each for the forward and reverse primers and 250 nm for the TaqMan probes (IBA BioTAGnologies, Göttingen, Germany). The same batch of cDNA $(20 \mu l)$ was used to determine the cycle of threshold of the TGF- β gene and MLN51 as housekeeping gene in triplicate reactions. Because the amplification efficiencies are close to 1 (as assessed by template dilution), it is possible to apply the following equation to relate the amount of the cytokine genes to $MLN51$: $2^{(\text{ct cytokine} - \text{ct } MLN51)}$.

Flow cytometry

For surface immunostaining PE-, APC-, and FITClabelled mAb against human CD3, CD4, CD8, TCR- $\gamma\delta$, V₂9, V δ 1, V δ 2, CD25 and LAP, and respectively mouse and rat isotype controls as well as human serum were employed. Inactivated normal human serum was used for blocking unspecific binding. Cells were washed with fluorescence-activated cell sorting (FACS) buffer (0-5% bovine serum albumin in PBS) and stained on ice for 10 min with optimal dilution. After washing, cells were analysed by flow cytometry (FACS Calibur and CELLQUEST software; Becton/Dickinson, Heidelberg, Germany) using a live gate set around viable lymphocytes based on their forward scatter/side scatter (FSC/SSC) characteristics. 50 000 cells per FSC/SCC gate were measured.

FoxP3 expression of purified CD4⁺ T cells and $\gamma\delta$ T cells was analysed by flow cytometry using APC-labelled antihuman FoxP3 antibody and the FoxP3 staining buffer set according to the manufacturer's instruction (Miltenyi Biotec). Before FoxP3 staining, the unlabelled $CD4^+$ T-cell fraction was stained with anti-human CD4-FITC mAb (BD Bioscience) and anti-human CD25-PE mAb (BD Bioscience). The $\gamma\delta$ T-cell fraction was already labelled and was counterstained with FITC-labelled Streptavidin (BD Bioscience).

For intracellular staining cells were stained with APClabelled mAb against human IL-2, IL-10 and IFN- γ as well as surface markers as described above in 0-5% saponin buffer (Sigma) for 30 min in the dark at room temperature. Cells were washed in 0-5% saponin and resuspended in FACS buffer and analysed by flow cytometry using a gate set around the lymphocyte population based on their FSC/SSC characteristics. 50 000 cells per FSC/SCC gate were measured.

To determine the proliferation of CFSE-labelled CD4⁺ T cells in mono- and coculture by flow cytometry the basic setting of the FACS was adjusted after 1 day of culture. A live gate was set around viable lymphocytes based on their FSC/SSC characteristics. Additionally, directly before measuring 1 µl propidium iodide (Sigma) was added to exclude necrotic cells (exclusion of PI^+ cells). 50 000 cells per FSC/ SCC gate were measured. The proliferation (reduction of CFSE intensity, CFSE^{dim}) was determined on day 6. Data analysis was carried out using FLOWJ^O (version 8.5.2; Tree Star Inc., Olten, Switzerland). To exclude cocultured cells, $\gamma\delta$ T cells or CD4⁺ CD25⁺ T cells, a gate was set on CFSEpositive (labelled) cells before the evaluation of proliferating ($CFSE^{dim}$) $CD4^+$ T cells.

Immunofluorescence

CD4⁺ T cells and $v\delta$ T cells were isolated by MACS technology and thereafter cytospins were prepared from 4×10^5 cells per slide. These cytospins were air-dried overnight at room temperature and formalin-fixed before staining. Fixed cytospins were subjected to a heat-induced epitope retrieval step (2 min in sodium citrate buffer solution, pH 6.0) before incubation with antibodies.²¹ Cytospins were washed in Tris-buffered saline (TBS) with 0-5% human serum after each antibody incubation. Cytospins were incubated with the primary antibody against human FOXP3 (PCH101; eBiosciences, San Diego, CA, 1 : 200). Then, cytospins were incubated with secondary Alexa 488-labelled anti-rat antibody (Invitrogen, Carlsbad, CA, 1 : 100). Nuclei were counterstained with DAPI (Sigma, 1 : 1500) and slides were mounted in Fluoromount (DAKO, Hamburg, Germany). Images were acquired using a fluorescence microscope (AxioImager Z1) equipped with a CCD camera (AxioCam MRm) and processed with AXIOVISION software (Carl Zeiss Micro-Imaging, Inc., Göttingen, Germany).

Statistics

For statistical analysis Mann–Whitney U-test was used and calculations were made using spss for Windows SPSS, Chicago, IL. Values were expressed as mean (95% confidence intervals) and standard error of the mean (SEM). Differences were considered statistically significant for $P < 0.05$.

Results

Human $\gamma\delta$ T cells are unresponsive to standard TCR stimulation

Human $\gamma\delta$ T cells were isolated from PBMC of whole blood of healthy donors by MACS technology. The purity of these cells was determined by flow cytometry and only $\gamma\delta$ T cells with > 98% purity were used in *in vitro* assays (Fig. 1). Human $\gamma\delta$ T cells showed in vitro significantly less proliferation upon T-cell stimulation with anti-CD3/ CD28 mAb than $CD4^+$ T cells (Fig. 2a). However, proliferation indices of anti-CD3/CD28 ± rhuIL-2-stimulated $\gamma\delta$ T cells were comparable to those of CD8⁺ T cells and $CD4^+$ $CD25^+$ T cells (Fig. 2a). Furthermore, proliferation of $\gamma\delta$ T cells was induced by stimulation with the mycobacterial phosphoantigen isopentenyl pyrophosphate (IPP), which did not stimulate other T-cell populations (Fig. 2b).

Human $\gamma\delta$ T cells suppress CD4 T-cell proliferation

To investigate the suppressive potential of $\gamma\delta$ T cells, the proliferation of cocultured CD4⁺ T cells was measured by

CFSE labelling and flow cytometry. Figure 3 shows representative histograms of proliferating $CD4^+$ T cells (CFSEdim) in monoculture and allogeneic coculture either

Figure 2. $\gamma \delta$ T cells are unresponsive to standard T-cell receptor stimulation via CD3/C28. (a) Box plot of proliferation index PI $(-)$ of CD4⁺ T cells ($n = 6$), CD8⁺ T cells ($n = 5$), CD4⁺ CD25⁺ T cells ($n = 5$) and $\gamma \delta$ T cells ($n = 10$) after stimulation via anti-CD3/CD28 (white boxes) and anti-CD3/CD28 + recombinant human interleukin-2 (rhuIL-2; grey boxes) and (b) bar chart $(+)$ SEM) of PI $(-)$ of CD4⁺, CD8⁺, $\gamma\delta$ and CD4⁺ CD25⁺ T cells after stimulation with isopentenyl pyrophosphate + rhuIL-2. (NS, statistically not significant).

Figure 1. Fluorescence-activated cell sorting analysis of $\gamma\delta$ T-cell isolation of human peripheral blood mononuclear cells (PBMC) by magnetic antibody cell sorting (MACS). Histograms show human PBMC before MACS (left) and after MACS (middle) using phycoerythrin-labelled anti-T-cell receptor $\gamma\delta$ monoclonal antibody as well as isotype control (mouse immunoglobulin G1, right).

with $\gamma\delta$ T cells or CD4⁺ CD25⁺ T cells. To estimate the suppression of $CD4^+$ T-cell growth the percentage of proliferating cells in monocultures, e.g. 70-6% in Fig. 3(a), was set to 100%. $\gamma\delta$ T cells suppressed the growth of $CD4^+$ T cells at cell ratios as low as $1:4$ (Fig. 4a). Importantly, the suppressive capacity of $\gamma \delta$ T cells remained after the addition of rhuIL-2 while $CD4^+$ $CD25^+$ T cells lost their suppressive capacity in the presence of rhuIL-2 (Fig. 4b). In contrast to $CD4^+$ $CD25^+$ Treg cells, unstimulated $\gamma \delta$ T cells do not express CD25 (Fig. 5). Additionally, when looking at FOXP3 expression by immunofluorescence, $\gamma \delta$ T cells did not show nuclear staining while 8% $CD4^+$ T cells did (Fig. 6). In addition, FOXP3 expression analysed by flow cytometry was found to be negative in $\gamma\delta$ T cells but positive in 5% of purified CD4⁺ T cells (data not shown).

$\gamma\delta$ T cells secret both proinflammatory and antiinflammatory cytokines

Anti-CD3/CD28 stimulated $\gamma\delta$ T cells produced negligible amounts of IL-2 but high concentrations of both proand anti-inflammatory cytokines (Fig. 7). Similarly, FACS analysis of intracellular cytokines revealed high percentages of $\gamma\delta$ T cells producing IFN- γ (48.5 ± 14.7%), IL-10 $(13.3 \pm 11.4\%)$ and IL-4 $(13.0 \pm 5.3\%)$, but only a few $\gamma\delta$ T cells produced IL-2 (1.9 ± 1.8%). No coexpression of IFN- γ and IL-4 or IL-10 or IL-2 was found (data not shown). The cytokine profile of $\gamma\delta$ T cells was comparable with that of $CD4^+$ $CD25^+$ T cells because there were no statistically significant differences regarding the secretion of IL-2, IL-10 and IFN- γ (Fig. 7). However, $\gamma \delta$ T cells secreted more TGF- β than CD4⁺ CD25⁺ T cells (Fig. 7).

Next, we investigated whether increased TGF- β production originates from one $\gamma\delta$ T-cell subset (V δ 1 or V δ 2). Therefore, we quantified the relative TGF- β mRNA content in the different $\gamma\delta$ T-cell subsets isolated from peripheral blood (V δ 1 and V δ 2). Also, on the RNA level, TGF- β content was higher in $\gamma \delta$ T cells than in $\alpha \beta$ T cells (Fig. 8).

The V δ 1 subset showed increased TGF- β mRNA content compared with $V\delta 2$ T cells in six out of seven

Figure 3. Determination of CD4+ T-cell proliferation by flow cytometry. Representative histograms of anti-CD3/CD28 stimulated (a) and anti-CD3/CD28 + interleukin-2 (IL-2) stimulated (b) CD4⁺ T cells in monoculture (left row) and in allogeneic coculture with $\gamma \delta$ T cells (middle row) and $CD4^+$ $CD25^+$ T cells (right row) at a cell ratio of 1 : 1 on day 6.

Figure 4. $\gamma \delta$ T suppress the growth of CD4⁺ T cells. Bar chart of mean (+ SEM) CD4⁺ T-cell growth (%) after stimulation via anti-CD3/CD28 (a) and via anti-CD3/CD28 + recombinant human interleukin-2 (rhulL-2) (b) in allogeneic coculture with $\gamma \delta T$ cells (white, $n = 6$) and CD4⁺ CD25⁺ T cells (grey, $n = 5$). The growth of the CD4⁺ T cell in monoculture (red, $n = 7$) as shown in Fig. 3(a) (e.g. 70.6% proliferating cells) was set to 100%. Asterisks indicate statistical significance (*P < 0.05 and **P < 0.01 compared with CD4⁺ T-cell growth in monoculture).

donors (Fig. 8). Furthermore, we compared the expression of the latency associated peptide (LAP), an indirect marker of TGF- β protein expression, by flow cytometry. As LAP expression is increased in the V δ 1 subset compared to V δ 2 T cells (45 \cdot 0 ± 11 \cdot 7% versus 8 \cdot 8 ± 6 \cdot 1%, $P < 0.05$) the V δ 1 subset seems to be the main TGF- β producer.

Discussion

To the best of our knowledge, the present study provides the first evidence that human peripheral $\gamma \delta$ T cells are a potent type of regulatory T cells. Although they are FOXP3 negative, they strongly suppress T helper cell proliferation in an IL-2-independent way and produce high

Figure 5. $\gamma\delta$ T cells express no CD25. Dot plots of freshly isolated peripheral blood mononuclear cells stained for CD25 expression in CD4⁺ and $\gamma\delta$ T cells.

Figure 6. $\gamma\delta$ T cells are FOXP3 negative. Cytospins showing no expression of FOXP3 in the $\gamma\delta$ T-cell population (a) and some FOXP3positive T cells among the $CD4^+$ T cells labelled with Alexa Fluor 488 (green, red arrows) and counterstained with DAPI (blue nucleus) (magnification \times 400).

Figure 7. $\gamma\delta$ T cells secret both anti- and pro-inflammatory cytokines. Bar chart of mean (+ SEM) cytokine concentration (c, pg/ml) in 48 hr culture supernatants of anti-CD3/CD28-stimulated $\gamma \delta$ T cells (white, $n = 13$) and CD4⁺ CD25⁺ T cells (grey, $n = 13$).

amounts of TGF- β . Just as for CD4⁺ CD25⁺ T cells, human $\gamma\delta$ T cells seem to be unresponsive to anti-CD3/ CD28 stimulation in an IL-2-dependent manner, although $CDS⁺$ T cells were also unresponsive in the experiments presented here. Human $\gamma\delta$ T cells did proliferate upon stimulation with the mycobacterial phosphoantigen IPP showing the proliferative potential of human $\gamma\delta$ T cells.

Regulatory T cells are characterized by being anergic to anti-CD3/CD28 stimulation and acting suppressively. The most thoroughly investigated regulatory T cells are $CD4^+$ CD25⁺ T cells, which lack IL-2 production.²² Anergy

Figure 8. Transforming growth factor- β (TGF- β) messenger RNA content is higher in $\gamma\delta$ than in $\alpha\beta$ T cells and higher in the V δ 1 than V δ 2 T-cell subset. Bar chart (+ SEM) of mean copies of TGF- β per copy of housekeeping gene MLN51 as quantified by reverse transcription–polymerase chain reaction.

of $CD4^+$ $CD25^+$ T cells can be reversed by IL-2 stimulation. Like CD4⁺ CD25⁺ T cells, $\gamma\delta$ T cells show negligible IL-2 production and the addition of IL-2 to anti-CD3/CD28 stimulation increases $\gamma\delta$ T-cell proliferation though this increase is only small and the proliferation is still less than that of $CD4^+$ T cells. Furthermore, IL-2 can not only reverse anergy but also suppressive behaviour of $CD4^+$ $CD25^+$ T cells.^{22,23} Surprisingly, we found suppression by $\gamma\delta$ T cells to be IL-2 independent. In the context of inflammation, this IL-2 independency might be advantageous compared with CD4⁺ CD25⁺ T cells because other T cells might escape suppression by IL-2 secretion. The $\gamma\delta$ T cells are quite unresponsive so the suppressive function of this regulatory cell population is probably restricted to epithelial surfaces where they are enriched.

As far as one can tell from in vitro experiments the suppressive power of $\gamma\delta$ T cells is probably at least as strong as that of CD4⁺ CD25⁺ T cells. Like $\gamma\delta$ T cells, $CD4^+$ $CD25^+$ T cells are also a small cell population in health and disease, 24 but mediate potent suppression of CD4⁺ CD25⁻ T cells.^{25,26} Additionally, intraepithelial $\gamma\delta$ T cells from patients with coeliac disease were reported to suppress intraepithelial $\alpha\beta$ T cells²⁷ and tumour-infiltrating $\gamma \delta_1$ T cells were shown to suppress proliferation of naïve T cells via CD3.²⁸ However, in both studies neither healthy controls nor peripheral $\gamma\delta$ T cells were investigated, raising the question whether these findings are a feature of all $\gamma\delta$ T cells rather than the result of coeliac disease or tumour immunology.

In the present study we could show that human peripheral $\gamma\delta$ T cells are FOXP3 negative, a well-known marker for regulatory T cells.²⁹ However, FOXP3-negative regulatory T cells have also been described by others.^{30,31}

Although the exact mechanism of suppression is neither fully understood for CD4⁺ CD25⁺ T cells nor for $\gamma\delta$ T cells, the cytokines IL-10 and TGF- β have been proposed to play an important role. Increased TGF- β production by $\gamma\delta$ T cells was previously reported in nephritic mice and patients with coeliac disease.^{27,32} Our data show that human $\gamma\delta$ T cells are even stronger TGF- β producers than regulatory $CD4^+$ $CD25^+$ T cells. As the growth factor TGF- β is involved in the maintenance of epithelial integrity and intestinal immunological balance as well as in epithelial cell restitution,^{33–38} $\gamma \delta$ T cells might exert their regulatory and protective functions via TGF- β secretion. In addition, $\gamma \delta$ T cells can increase TGF- β production indirectly via IL-10 secretion, which in turn can stimulate other T cells to produce more TGF- β .³⁹

The V δ 1 T cells are mainly located in the epithelium, e.g. the intestinal epithelium, where they represent 70–90% of $\gamma\delta$ T cells.²¹ The V δ 1 T-cell subset seems to be the major source of TGF- β production because the number of V δ 1 T cells which express LAP, a TGF- β complex component and thereby indirect marker of TGF- β expression, was found to be higher than among V δ 2 T cells. Besides LAP expression, the TGF- β mRNA content in V δ 1 and V δ 2 T cells was determined. However, the mean increase in TGF- β mRNA in $V\delta1$ T cells was not statistically significant because of high standard deviations. Still, six out of seven donors had increased TGF- β mRNA in V δ 1 T cells compared with V δ 2 T cells when looking at the V δ 1: V δ 2 ratio. The V δ 1 T-cell subset was previously reported to have regulatory potential when looking at tumour-infiltrating lymphocyte clones. However, these so-called $\gamma \delta$ 1 Treg cells did not produce TGF- β or IL-10.²⁸

The high production of IFN- γ by $\gamma \delta$ T cells is probably important for defence against infectious and malignant diseases^{12,40,41} without necessarily triggering inflammation.^{6–9,19} Recently, $\gamma \delta$ T cells have also been reported to be able to suppress tumour cytotoxicity in spite of being potent IFN- γ producers.²⁸

In conclusion, human peripheral $\gamma\delta$ T cells are unresponisve to standard TCR stimulation and showed in vitro suppressive behaviour as well as production of both pro- and anti-inflammatory cytokines. Their suppressive behaviour is IL-2 independent and is at least as powerful as that of $CD4^+$ $CD25^+$ T cells, making them key players in the regulation of other T cells as well as of epithelial homeostasis within mucosal surfaces. Still, their strong proliferation upon mycobacterial antigen stimulation as well as their marked secretion of IFN- γ shows their potential to counteract intestinal infections as well as to suppress inflammatory reactions using their regulatory repertoire. Importantly, they are not only strong IFN- γ and IL-10 producers but also very strong TGF- β producers. The strongest $TGF-\beta$ production was found among the V δ 1 subset of $\gamma \delta$ T cells.

Acknowledgements

The work of the authors was supported by SFB633/B3 and SFB 633/Z1, the German competence network on irritable bowel disease and by a grant from the German Crohn's and Colitis foundation (DCCV).

Disclosures

The authors report no conflict of interest.

References

- 1 Kaufmann SH, Blum C, Yamamoto S. Crosstalk between $\alpha\beta$ T cells and $\gamma\delta$ T cells in vivo: activation of $\alpha\beta$ T-cell responses after $\gamma\delta$ T-cell modulation with the monoclonal antibody GL3. Proc Natl Acad Sci USA 1993; 90:9620–4.
- 2 Pennington DJ, Silva-Santos B, Shires J et al. The inter-relatedness and interdependence of mouse T cell receptor $\gamma \delta$ + and $\alpha \beta$ + cells. Nat Immunol 2003; 4:991–8.
- 3 Roberts SJ, Smith AL, West AB, Wen L, Findly RC, Owen MJ, Hayday AC. T-cell $\alpha\beta$ + and $\gamma\delta$ + deficient mice display abnormal but distinct phenotypes toward a natural, widespread infection of the intestinal epithelium. Proc Natl Acad Sci USA 1996; 93:11774–9.
- 4 King DP, Hyde DM, Jackson KA et al. Cutting edge: protective response to pulmonary injury requires $\gamma \delta$ T lymphocytes. J Immunol 1999; 162:5033–6.
- 5 Hoffmann JC, Peters K, Henschke S, Herrmann B, Pfister K, Westermann J, Zeitz M. Role of T lymphocytes in rat 2,4,6-

trinitrobenzene sulphonic acid (TNBS) induced colitis: increased mortality after $\gamma\delta$ T cell depletion and no effect of alphabeta T cell depletion. Gut 2001; 48:489–95.

- 6 Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial $\gamma \delta$ T cells. Proc Natl Acad Sci USA 2002; 99:14338–43.
- 7 Kühl AA, Loddenkemper C, Westermann J, Hoffmann JC. Role of $\gamma\delta$ T cells in inflammatory bowel disease. Pathobiology 2002; 70:150–5.
- 8 Tsuchiya T, Fukuda S, Hamada H, Nakamura A, Kohama Y, Ishikawa H, Tsujikawa K, Yamamoto H. Role of $\gamma\delta$ T cells in the inflammatory response of experimental colitis mice. J Immunol 2003; 171:5507–13.
- 9 Inagaki-Ohara K, Chinen T, Matsuzaki G et al. Mucosal T cells bearing TCR $\gamma\delta$ play a protective role in intestinal inflammation. J Immunol 2004; 173:1390–8.
- 10 Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 $\gamma\delta$ T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167–74.
- 11 Locke NR, Stankovic S, Funda DP, Harrison LC. TCR $\gamma\delta$ intraepithelial lymphocytes are required for self-tolerance. J Immunol 2006; 176:6553–9.
- 12 Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. $\gamma\delta$ T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003; 198:433–42.
- 13 Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC. The distinct contributions of murine T cell receptor (TCR) $\gamma \delta$ + and TCR $\alpha \beta$ + T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198:747–55.
- 14 Haas W, Pereira P, Tonegawa S. $\gamma\delta$ cells. Annu Rev Immunol 1993; 11:637–85.
- 15 Boismenu R, Havran WL. Modulation of epithelial cell growth by intraepithelial $\gamma \delta$ T cells. Science 1994; 266:1253-5.
- 16 Havran WL. A role for epithelial $\gamma \delta$ T cells in tissue repair. Immunol Res 2000; 3:63–9.
- 17 Havran WL, Jameson JM, Witherden DA. Epithelial cells and their neighbors. III. Interactions between intraepithelial lymphocytes and neighboring epithelial cells. Am J Physiol Gastrointest Liver Physiol 2005; 289:G627–30.
- 18 Komori HK, Meehan TF, Havran WL. Epithelial and mucosal $\gamma \delta$ T cells. Curr Opin Immunol 2006; 18:534–8.
- 19 Kuhl AA, Pawlowski NN, Grollich K, Loddenkemper C, Zeitz M, Hoffmann JC. Aggravation of intestinal inflammation by depletion/deficiency of $\gamma\delta$ T cells in different types of IBD animal models. J Leukoc Biol 2007; 81:168–75.
- 20 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402–8.
- 21 Deusch K, Luling F, Reich K, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the $\gamma\delta$ T cell receptor, the CD8 accessory molecule and preferentially uses the $V\delta1$ gene segment. Eur J Immunol 1991; 21:1053–9.
- 22 Shevach EM. $CD4^+$ $CD25^+$ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389–400.
- 23 Vieira PL, Christensen JR, Minaee S et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring $CD4^+$ $CD25^+$ regulatory T cells. J Immunol 2004; 172:5986–93.
- 24 Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory $CD4^+$ CD25^(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128:1868–78.
- 25 Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human $CD4^+$ $CD25^+$ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285–94.
- 26 Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4⁺ CD25⁺ regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002; 196:247–53.
- 27 Bhagat G, Naiyer AJ, Shah JG, Harper J, Jabri B, Wang TC, Green PH, Manavalan IS. Small intestinal CDS^+ TCR $\gamma \delta^+$ NKG2A⁺ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J Clin Invest 2008; 118:281–93.
- 28 Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating $\gamma \delta$ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007; 27:334–48.
- 29 Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212:8–27.
- 30 Hillebrands JL, Whalen B, Visser JT et al. A regulatory $CD4^+$ T cell subset in the BB rat model of autoimmune diabetes expresses neither CD25 nor Foxp3. J Immunol 2006; 177:7820–32.
- 31 Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both $F\exp 3^{+}$ CD25⁺ and $F\exp 3^{-}$ CD25⁻ CD4⁺ regulatory T cells. J Immunol 2006; 177:7634–44.
- 32 Wu H, Knight JF, Alexander SI. Regulatory gamma delta T cells in Heymann nephritis express an invariant $V\gamma6/V\delta1$ with a canonical CDR3 sequence. Eur J Immunol 2004; 34:2322–30.
- 33 Hahm KB, Im YH, Parks TW, Park SH, Markowitz S, Jung HY, Green J, Kim SJ. Loss of transforming growth factor β signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001; 49:190–8.
- 34 Beck PL, Rosenberg IM, Xavier RJ, Koh T, Wong JF, Podolsky DK. Transforming growth factor- β mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol 2003; 162:597–608.
- 35 Mammen JM, Matthews JB. Mucosal repair in the gastrointestinal tract. Crit Care Med 2003; 8(Suppl):S532–7.
- 36 Dignass AU. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001; 7:68–77.
- 37 Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110:975–84.
- 38 Thompson JS, Saxena SK, Sharp JG. Regulation of intestinal regeneration: new insights. Microsc Res Tech 2000; 51:129– 37.
- 39 Fuss IJ, Boirivant M, Lacy B, Strober W. The interrelated roles of TGF- $\gamma\delta$ and IL-10 in the regulation of experimental colitis. J Immunol 2002; 168:900–8.
- 40 Lopez RD. Human $\gamma \delta$ -T cells in adoptive immunotherapy of malignant and infectious diseases. Immunol Res 2002; 3:207–21.
- 41 Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human $v\delta$ T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23:14–8.